Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2019.37.15_suppl.1084
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

The Impacts of Inclusion in Clinical Trials on Outcomes Among Patients With Metastatic Breast Cancer (MBC)

PLoS ONE
Multidisciplinary
2016English

2′-Behenoyl-Paclitaxel Conjugate Containing Lipid Nanoparticles for the Treatment of Metastatic Breast Cancer

Cancer Letters
Cancer ResearchOncology
2013English

Analysis of Eribulin Mesylate Dosing Modifications Impact on Administration Persistence in Patients With Metastatic Breast Cancer (Mbc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Treatment of Oral Cancer Using Magnetized Paclitaxel

Oncotarget
Oncology
2018English

Prolonged Survival of Patients Receiving Trastuzumab Beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

Oncology Research and Treatment
Cancer ResearchOncologyHematology
2005English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Oral Fluoropyrimidines Among the New Drugs for Patients With Metastatic Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2001English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Changing Treatment Paradigms in Metastatic Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy